Eltrombopag 12.5mg (Eltrombopag)

Description of Revolade 12.5mg (Eltrombopag 12.5mg)

Revolade 12.5mg (Eltrombopag 12.5mg) is a prescription medicine which is used under the guidance of the doctor.

Revolade 12.5mg (Eltrombopag 12.5mg) medicine may be used as part of a combination therapy. Thereby medicine may need to take it with other medications.

Medical use /Indication of Revolade 12.5mg (Eltrombopag 12.5mg)

Revolade 12.5mg (Eltrombopag 12.5mg) is mainly indicated for the treatment of patients having :

•  Reduced platelet levels due to chronic immune thrombocytopenia
• Reduced platelet counts due to chronic hepatitis C virus infection

Severe aplastic Anemia :

• First line treatment of severe aplastic Anemia
• Treatment of refractory severe aplastic Anemia

Mechanism of Action Revolade 12.5mg (Eltrombopag 12.5mg)

Revolade be part of class of meidcines called thrombopoietin (TPO) receptor agonists. A classification of medicines is aassociation of medications which work in a similar way. These mediciens are often used to treat similar conditions. Revolade works by raise cells in bone marrow andleads these cells to make various platelets. This effect reducesthe risk of bleeding.

Absorption of Revolade 12.5mg (Eltrombopag 12.5mg)

peak plasma concentration is 2-6 hours

Distribution of Revolade 12.5mg (Eltrombopag 12.5mg)

highly human plasma protein bounding is >99% and in blood plasma level is 50% to 79%

Metabolism of Revolade 12.5mg (Eltrombopag 12.5mg)

predominantly metabolised through cleavage, oxidation and conjugation with glucuronic acid.

Excretion of Revolade 12.5mg (Eltrombopag 12.5mg)

Revolade 12.5mg (Eltrombopag 12.5mg) eliminated primarily via feces 59%, along with 31% via renally excreted
Half-life of Revolade 12.5mg (Eltrombopag 12.5mg) healthy patients is 21-23 hours and idiopathic thrombocytopenic purpura is 26-35 hours.

Side effects of Revolade 12.5mg (Eltrombopag 12.5mg)

Common side effects:

• low red blood cells
• nausea
• fever
• weakness
• pain in head
• cough
• decreased appetite
• flu
• diarrhoea.

Serious side effects:

• Urine in dark colour
• Yellowing of your skin
• Abdomen swelling
• Confusion
• Chest pain
• Dyspnea
• Cloudy vision
• Sensitivity to light
• Seeing circles around lights
• Swelling of legs.

Precautions of Revolade 12.5mg (Eltrombopag 12.5mg)

The medicines causes warning condition, call the doctor while new medication interaction Disease progression warning: Avoid using the medicine while the patients have myelodysplastic syndrome (MDS), will increases the risk of death.
If other blood clot risk factors, then avoid the medicine because it will increase platelet counts and blood clots.
If the patients have cataracts, avoid the medicine due to the medicine  effects cataracts and make the condition worse.

Drug interaction of Revolade 12.5mg (Eltrombopag 12.5mg)

• Revolade 12.5mg (Eltrombopag 12.5mg)interaction with these medicines ezetimibe, glyburide, Olmesartan, repaglinide, valsartan, imatinib, irinotecan, lapatinib, methotrexate, mitoxantrone, Bosentan, sulfasalazine, and topotecan irinotecan leads increase of side effects. hence the doctor may reduce your dosage of these medcines if required.
•  Revolade 12.5mg (Eltrombopag 12.5mg) co administration with Cholesterol-reducing medicines like atorvastatin, fluvastatin, rosuvastatin, pravastatin, and simvastatin, pitavastatin. Have high side effects can contains muscle pain. The doctor may reduce the dosage of your cholesterol medicines.
• Revolade 12.5mg (Eltrombopag 12.5mg) concomitant use with Antacids, vitamins, or supplements which involves Ca, Al, Fe, Se, Zn, or Mg. To stop interactions, then take Revolade two hours before or four hours after administrating any of these products.

Pregnancy of Revolade 12.5mg (Eltrombopag 12.5mg)

Pregnancy category is C
Use the Revolade 12.5mg (Eltrombopag 12.5mg) with caution if asset outweigh risks. Animal studies reveal risk and human studies not available or neither animal nor human studies done.

Lactation of Revolade 12.5mg (Eltrombopag 12.5mg)

The presence of Revolade 12.5mg (Eltrombopag 12.5mg) or metabolites in human milk, the medicine has possible serious side effects for breastfed child. The medicine is not recommended during breast feeding

Dosage of Revolade 12.5mg (Eltrombopag 12.5mg)

Chronic Immune Thrombocytopenia:

The recommended dose of Revolade has Initial: 50 mg PO qDay Adjust dose to achieve Control platelet count (Plt) >50 x 10^9/L to reduces risk of bleeding; not to exceed 75 mg/day

Chronic Hepatitis C-associated Thrombocytopenia:

The recommended dose of Revolade has Initial: 25 mg PO qDay Dose is Adjust in 25 mg accretion q2weeks PRN to attain target Plt needed to start/control antiviral therapy with pegylated interferon and ribavirin; not to exceed 100 mg/day During antiviral therapy, regulate dose to stop dose reductions of peginterferon Severe Aplastic Anemia
First-line therapy: Concomitant use with standard immunosuppressive therapy, for patients with serious aplastic Anemia (SAA) The recommended dose of Revolade: 150 mg PO qDay for 6 months Do not give more than starting dose; total duration is 6 months

Refractory SAA:

The medicine given for this condition who fail to respond enough to at least 1 before immunosuppressive therapy The recommended dose of Revolade: 50 mg PO qDay Adjust dose in 50-mg accretion q2Weeks PRN to attain target Plt ≥50 x 10^9/L as required; not exceed 150 mg/day; may take up to 16 weeks for hematologic response.

Storage of Revolade 12.5mg (Eltrombopag 12.5mg)

Store at room temperature 20℃ and 25℃.
Discard the left-out medicine if not used within 30 minutes

Missed dose of Revolade 12.5mg (Eltrombopag 12.5mg)

In case of missed dose, patients must consult with medical practitioner and follow the instructions given by them. thereby missed dose should be avoid and follow the regular dosing schedule.